)
United Therapeutics (UTHR) investor relations material
United Therapeutics Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Commercial performance and outlook
Q3 revenue reached a record $833 million; TYVASO revenue also set a record at $504 million.
More than 1,000 referrals across the commercial portfolio in October set a new monthly record; management expects added sales teams to support Q4 and 2027 momentum.
TYVASO in PH-ILD
PH-ILD remains a key growth driver; management expects newly diagnosed patients to transition to TYVASO DPI as the settlement’s label and communication changes take effect, with momentum expected in Q4 and 2027.
Timing of payer coverage changes will vary by payer; management hopes updates align with the beginning-of-year reauthorization process.
Management plans close monitoring of settlement compliance and said it would act to protect its intellectual property if the agreed guardrails are not followed.
Management expressed comfort with current rebates but said it would assess the settlement’s prospective gross-to-net impact over time.
TYVASO in IPF
The FDA accepted the nebulized TYVASO sNDA for IPF, with a PDUFA date of April 26; management expects broad use and does not anticipate a price change.
TETON results were described as generalizable across subgroups and on background therapy; use could be adjunctive, refractory, or potentially first-line, guided by physician judgment and patient needs.
Payer discussions and Medicare local coverage determination work are ongoing; teams are preparing, with further progress expected in 2027 as the PDUFA date approaches.
European partner Ferrer filed with the EMA for nebulized TYVASO in IPF in the regions covered by its agreement.
- Record TYVASO momentum and multiple 2027 pipeline catalysts define the outlook.UTHR
UBS Global Biopharma Conference 2026 - Record revenue and product growth offset lower earnings and pipeline execution risks.UTHR
Q3 2026 - Expanding into pulmonary fibrosis with strong clinical data and major revenue growth targets.UTHR
Morgan Stanley 24th Annual Global Healthcare Conference - Disruptive therapies and organ manufacturing drive exponential growth and innovation.UTHR
Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum - Pulmonary fibrosis breakthroughs and 14 launches drive a projected 10x revenue surge.UTHR
12th Annual Cantor Fitzgerald Global Healthcare Conference - Aggressive product launches and innovation aim for $50–100B revenue and industry leadership.UTHR
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenues fell 2% to $783.3M, but net income rose 8% to $333M on Tyvaso DPI growth.UTHR
Q2 2026 - Record growth, breakthrough pulmonary fibrosis results, and pioneering xenotransplantation trials.UTHR
Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum - Q2 2024 revenue up 20% to $715M, net income $278.1M, Tyvaso led growth, $1B buyback completed.UTHR
Q2 2024
)
)
)
)
)
)
)
)